Other languages Werewolf Therapeutics, Inc.

Equities

HOWL

US95075A1079

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-01 EDT			5-day change	1st Jan Change
6.02 ^USD	-3.53%		-5.79%	+55.96%

04-23	Werewolf Therapeutics, Inc. Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease at AAI Annual Meeting	CI
04-05	Werewolf Therapeutics, Inc. Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Werewolf Therapeutics, Inc. Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease at AAI Annual Meeting	04-23
Werewolf Therapeutics, Inc. Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics	04-05
Werewolf Therapeutics' Q4 Net Loss Narrows	03-07
Werewolf Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-07
Werewolf Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-07
Werewolf Therapeutics, Inc. Appoints Michael Atkins to its Board of Directors	01-04
Werewolf Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14
Sector Update: Health Care Stocks Stronger Late Afternoon	11-03
Sector Update: Health Care	11-03
Top Midday Gainers	11-03
Werewolf Therapeutics, Inc. to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer's 38th Annual Meeting	23-10-31
Top Premarket Decliners	23-09-25
Werewolf Therapeutics, Inc. Announces the Investigational New Drug Application Clearance of JZP898 (Formerly Wtx-613), an Engineered IFN Indukine Molecule	23-08-10
Werewolf Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
Werewolf Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11
Werewolf Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-23
Werewolf Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-23
Werewolf Therapeutics, Inc. Anticipates Multiple Catalysts as the Company Progress the Company's Two Clinical Stage Programs, WTX-124 and WTX-330	23-03-23
Werewolf Therapeutics Doses First Patient in Phase 1 Study of Potential Solid Tumor Drug	23-02-24
Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1 Study of WTX-330	23-02-24

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Werewolf Therapeutics, Inc.

Equities

HOWL

US95075A1079

Other languages

Filters